The role of booster vaccination and ongoing viral evolution in seasonal circulation of SARS-CoV-2

Author:

Kraay A. N. M.12ORCID,Gallagher M. E.3,Ge Y.4,Han P.5,Baker J. M.5,Koelle K.6,Handel A.78,Lopman B. A.5

Affiliation:

1. Department of Kinesiology and Community Health, University of Illinois at Urbana-Champaign, Urbana, IL, USA

2. Institute for Genomic Biology, University of Illinois at Urbana-Champaign, Urbana, IL, USA

3. Johns Hopkins University Applied Physics Laboratory, Laurel, MD, USA

4. School of Health Professions – Public Health, University of Southern Mississippi, Hattiesburg, MS, USA

5. Rollins School of Public Health, Emory University, Atlanta, GA, USA

6. Department of Biology, Emory University, Atlanta, GA, USA

7. Department of Epidemiology & Biostatistics, University of Georgia, Athens, GA, USA

8. Center for the Ecology of Infectious Diseases, University of Georgia, Athens, GA, USA

Abstract

Periodic resurgences of COVID-19 in the coming years can be expected, while public health interventions may be able to reduce their intensity. We used a transmission model to assess how the use of booster doses and non-pharmaceutical interventions (NPIs) amid ongoing pathogen evolution might influence future transmission waves. We find that incidence is likely to increase as NPIs relax, with a second seasonally driven surge expected in autumn 2022. However, booster doses can greatly reduce the intensity of both waves and reduce cumulative deaths by 20% between 7 January 2022 and 7 January 2023. Reintroducing NPIs during the autumn as incidence begins to increase again could also be impactful. Combining boosters and NPIs results in a 30% decrease in cumulative deaths, with potential for greater impacts if variant-adapted boosters are used. Reintroducing these NPIs in autumn 2022 as transmission rates increase provides similar benefits to sustaining NPIs indefinitely (307 000 deaths with indefinite NPIs and boosters compared with 304 000 deaths with transient NPIs and boosters). If novel variants with increased transmissibility or immune escape emerge, deaths will be higher, but vaccination and NPIs are expected to remain effective tools to decrease both cumulative and peak health system burden, providing proportionally similar relative impacts.

Funder

NSF

NIAID

NIH/NIGMS

Publisher

The Royal Society

Subject

Biomedical Engineering,Biochemistry,Biomaterials,Bioengineering,Biophysics,Biotechnology

Reference20 articles.

1. CDC. 2020 COVID Data Tracker . Centers for Disease Control and Prevention [Internet]. See https://covid.cdc.gov/covid-data-tracker (accessed 21 February 2022).

2. CDC. 2022 Different COVID-19 Vaccines . Centers for Disease Control and Prevention [Internet]. See https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines.html (accessed 21 February 2022).

3. US Food and Drug Administration. 2022 Coronavirus (COVID-19) Update: FDA Authorizes Moderna and Pfizer-BioNTech COVID-19 Vaccines for Children Down to 6 Months of Age [Internet]. FDA. See https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-moderna-and-pfizer-biontech-covid-19-vaccines-children (accessed 23 June 2022).

4. Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel

5. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3